home LATEST ONCOPRESCRIBE UPDATES Late Breaking Abstract – ASCO 2022: Survival Benefit with TRODELVY® in Hormone Receptor Positive/HER2-Negative Metastatic Breast CancerLate Breaking Abstract – ASCO 2022: Adagrasib in KRAS G12C Mutated Non Small Cell Lung CancerLate Breaking Abstract – ASCO 2022: Adjuvant Radiotherapy May Be Omitted in Select Patients with Luminal A Breast CancerLate Breaking Abstract – ASCO 2022: Circulating Tumor DNA in the Peripheral Blood Can Guide Adjuvant Therapy Decision in Stage II Colon CancerLate Breaking Abstract – ASCO 2022: IMBRUVICA® plus Bendamustine and Rituximab for Older Patients with Untreated Mantle Cell LymphomaFDA Approves OPDIVO® Combination for Advanced Esophageal CarcinomaConsider Guideline-Recommended Biomarker Testing as an Integral Component of NSCLC CareFDA Approves KYMRIAH® for Relapsed or Refractory Follicular Lymphoma SHOW MORE FDAApprovals Meeting Updates Hem/OncUpdates Symptom Management NEW REGIMENS ADDEDResearch RegimensIDHIFA® - for Acute Myeloid Leukemia XOSPATA® - for Acute Myeloid Leukemia PARAPLATIN® and VEPESID® with IMFINZI® - for Small Cell Lung CancerIMFINZI® Maintenance - Small Cell Lung CancerSingle Agent PEMAZYRE® - for Cholangiocarcinoma Curbside ConsultationBiomarker Testing in NSCLC-Special IssueImmuno-OncologyPrecision OncologyCOVID-19 Associated Coagulopathy: Diagnosis and ManagementTTP, HUS and aHUS: Different diseases – Different treatmentsHER2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateDual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal TumorsFDA Approves ENDARI®, A New Treatment for Sickle Cell DiseaseSHOW MORE